Composition

each tablet contains Cefpodoxime 100 & 200 mg

Action

Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases.

The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. Cefpodoxime has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections:

Aerobic Gram-positive microorganisms:
- *Staphylococcus aureus* (including penicillinase-producing strains)
- *Streptococcus pneumoniae* (excluding penicillin-resistant strains)
- *Streptococcus pyogenes*

Aerobic Gram-negative microorganisms:
- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Proteus mirabilis*
- *Haemophilus influenzae* (including beta-lactamase producing strains)
- *Moraxella (Branhamella) catarrhalis*
- *Neisseria gonorrhoeae* (including penicillinase-producing strains)

The following in vitro data are available, but their clinical significance is unknown. Cefpodoxime exhibits in vitro minimum inhibitory concentrations (MICs) of ≤ 2.0 mcg/mL against most (≥ 90%) of isolates of the following microorganisms. However, the safety and efficacy of cefpodoxime in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

Aerobic Gram-positive microorganisms:
- *Streptococcus agalactiae*
- *Streptococcus spp.* (Groups C, F, G)

Aerobic Gram-negative microorganisms:
- *Citrobacter diversus*
- *Klebsiella oxytoca*
- *Proteus vulgaris*
- *Providencia rettgeri*
- *Haemophilus parainfluenzae*

Anaerobic Gram-positive microorganisms:
- *Peptostreptococcus magnus*

Pharmacokinetics

Absorption and Excretion
Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically. Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime in vivo.

**Effects of Food**

The extent of absorption (mean AUC) and the mean peak plasma concentration increased when film-coated tablets were administered with food. Following a 200 mg tablet dose taken with food, the AUC was 21 to 33% higher than under fasting conditions, and the peak plasma concentration averaged 3.1 mcg/mL in fed subjects versus 2.6 mcg/mL in fasted subjects. Time to peak concentration was not significantly different between fed and fasted subjects.

When a 200 mg dose of the suspension was taken with food, the extent of absorption (mean AUC) and mean peak plasma concentration in fed subjects were not significantly different from fasted subjects, but the rate of absorption was slower with food (48% increase in Tmax).

**Distribution**

Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.

**Skin Blister**

Following multiple-dose administration every 12 hours for 5 days of 200 mg or 400 mg cefpodoxime proxetil, the mean maximum cefpodoxime concentration in skin blister fluid averaged 1.6 and 2.8 mcg/mL, respectively. Skin blister fluid cefpodoxime levels at 12 hours after dosing averaged 0.2 and 0.4 mcg/mL for the 200 mg and 400 mg multiple-dose regimens, respectively.

**Tonsil Tissue**

Following a single, oral 100 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in tonsil tissue averaged 0.24 mcg/g at 4 hours post-dosing and 0.09 mcg/g at 7 hours post-dosing. Equilibrium was achieved between plasma and tonsil tissue within 4 hours of dosing. No detection of cefpodoxime in tonsillar tissue was reported 12 hours after dosing. These results demonstrated that concentrations of cefpodoxime exceeded the MIC90 of S. pyogenes for at least 7 hours after dosing of 100 mg of cefpodoxime proxetil.

**Lung Tissue**

Following a single, oral 200 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in lung tissue averaged 0.63 mcg/g at 3 hours post-dosing, 0.52 mcg/g at 6 hours post-dosing, and 0.19 mcg/g at 12 hours post-dosing. The results of this study indicated that cefpodoxime penetrated into lung tissue and produced sustained drug concentrations for at least 12 hours after dosing at levels that exceeded the MIC90 for S. pneumoniae and H. influenzae.

**CSF**

Adequate data on CSF levels of cefpodoxime are not available.

**Effects of Decreased Renal Function**

Elimination of cefpodoxime is reduced in patients with moderate to severe renal impairment (< 50 mL/min creatinine clearance). In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours. In subjects with moderate (30 to 49 mL/min creatinine clearance) or severe renal impairment (5 to 29 mL/min creatinine clearance), the half-life increased to 5.9 and 9.8 hours, respectively. Approximately 23% of the administered dose was cleared from the body during a standard 3-hour hemodialysis procedure.

**Effect of Hepatic Impairment (cirrhosis)**

Absorption was somewhat diminished and elimination unchanged in patients with cirrhosis. The mean cefpodoxime $T_{1/2}$ and renal clearance in cirrhotic patients were similar to those derived in studies
of healthy subjects. Ascites did not appear to affect values in cirrhotic subjects. No dosage adjustment is recommended in this patient population.

**Pharmacokinetics in Elderly Subjects**

Elderly subjects do not require dosage adjustments unless they have diminished renal function. In healthy geriatric subjects, cefpodoxime half-life in plasma averaged 4.2 hours (vs 3.3 in younger subjects) and urinary recovery averaged 21% after a 400 mg dose was administered every 12 hours. Other pharmacokinetic parameters (Cmax, AUC, and Tmax) were unchanged relative to those observed in healthy young subjects.

**Indications**

CEFPO is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.

Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. **Acute otitis media** caused by *Streptococcus pneumoniae* (excluding penicillin-resistant strains), *Streptococcus pyogenes*, *Haemophilus influenzae* (including beta-lactamase-producing strains), or *Moraxella* (Branhamella) *catarrhalis* (including beta-lactamase-producing strains).

**Pharyngitis and/or tonsillitis** caused by *Streptococcus pyogenes*.

**Community-acquired pneumonia** caused by *S. pneumoniae* or *H. influenzae* (including beta-lactamase-producing strains).

**Acute bacterial exacerbation of chronic bronchitis** caused by *S. pneumoniae*, *H. influenzae* (non-beta-lactamase-producing strains only), or *M. catarrhalis*. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of *H. influenzae*.

**Acute, uncomplicated urethral and cervical gonorrhea** caused by *Neisseria gonorrhoeae* (including penicillinase-producing strains).

**Acute, uncomplicated ano-rectal infections in women** due to *Neisseria gonorrhoeae* (including penicillinase-producing strains).

**Uncomplicated skin and skin structure infections** caused by *Staphylococcus aureus* (including penicillinase-producing strains) or *Streptococcus pyogenes*. Abscesses should be surgically drained as clinically indicated.

**Acute maxillary sinusitis** caused by *Haemophilus influenzae* (including beta-lactamase-producing strains), *Streptococcus pneumoniae*, and *Moraxella catarrhalis*.

**Uncomplicated urinary tract infections (cystitis)** caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, or *Staphylococcus saprophyticus*.

**Contraindications**

Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.

**Warnings & Precautions**

BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC
REACTION TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.

*Clostridium difficile* associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefpodoxime proxetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

*C difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management. Protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

A concerted effort to monitor for *C. difficile* in cefpodoxime-treated patients with diarrhea was undertaken because of an increased incidence of diarrhea associated with *C. difficile* in early trials in normal subjects. *C. difficile* organisms or toxin was reported in 10% of the cefpodoxime-treated adult patients with diarrhea; however, no specific diagnosis of pseudomembranous colitis was made in these patients.

In post-marketing experience outside the United States, reports of pseudomembranous colitis associated with the use of cefpodoxime proxetil have been received.

**General**

In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of cefpodoxime proxetil should be reduced because high and prolonged serum antibiotic concentrations can occur in such individuals following usual doses. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics.

As with other antibiotics, prolonged use of cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Prescribing cefpodoxime proxetil in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**Pregnancy**

*Pregnancy Category B*

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

**Nursing Mothers**

Cefpodoxime is excreted in human milk. In a study of 3 lactating women, levels of cefpodoxime in human milk were 0%, 2% and 6% of concomitant serum levels at 4 hours following a 200 mg oral dose of cefpodoxime proxetil. At 6 hours post-dosing, levels were 0%, 9% and 16% of concomitant serum levels. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
**Pediatric Use**
Safety and efficacy in infants less than 2 months of age have not been established.

**Geriatric Use**
No overall differences in effectiveness or safety were observed between the elderly and younger patients. Other pharmacokinetic parameters were unchanged relative to those observed in healthy younger subjects.

Dose adjustment in elderly patients with normal renal function is not necessary

**Adverse Reactions**
In clinical trials using multiple doses of cefpodoxime proxetil film-coated tablets, 4696 patients were treated with the recommended dosages of cefpodoxime (100 to 400 mg Q 12 hours). There were no deaths or permanent disabilities thought related to drug toxicity. Adverse events thought possibly or probably related to cefpodoxime in multiple-dose clinical trials (N=4696 cefpodoxime-treated patients) were:

**Incidence Greater Than 1%:**
Diarrhea 7.0%
Diarrhea or loose stools were dose-related: decreasing from 10.4% of patients receiving 800 mg per day to 5.7% for those receiving 200 mg per day. Of patients with diarrhea, 10% had *C. difficile* organism or toxin in the stool.

<table>
<thead>
<tr>
<th>Incidence</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.0%</td>
<td>Diarrhea</td>
</tr>
<tr>
<td>3.3%</td>
<td>Nausea</td>
</tr>
<tr>
<td>1.0%</td>
<td>Vaginal Fungal Infections</td>
</tr>
<tr>
<td>1.3%</td>
<td>Vulvovaginal Infections</td>
</tr>
<tr>
<td>1.2%</td>
<td>Abdominal Pain</td>
</tr>
<tr>
<td>1.0%</td>
<td>Headache</td>
</tr>
</tbody>
</table>

**Incidence Less Than 1%: By body system in decreasing order:**

**Body** - fungal infections, abdominal distention, malaise, fatigue, asthenia, fever, chest pain, back pain, chills, generalized pain, abnormal microbiological tests, moniliasis, abscess, allergic reaction, facial edema, bacterial infections, parasitic infections, localized edema, localized pain.

**Cardiovascular** - congestive heart failure, migraine, palpitations, vasodilation, hematoma, hypertension, hypotension.

**Digestive** - vomiting, dyspepsia, dry mouth, flatulence, decreased appetite, constipation, oral moniliasis, anorexia, eructation, gastritis, mouth ulcers, gastrointestinal disorders, rectal disorders, tongue disorders, tooth disorders, increased thirst, oral lesions, tenesmus, dry throat, toothache.

**Hemic and Lymphatic** - anemia.

**Metabolic and Nutritional** - dehydration, gout, peripheral edema, weight increase.

**Musculoskeletal** - myalgia.

**Nervous** - dizziness, insomnia, somnolence, anxiety, shakiness, nervousness, cerebral infarction, change in dreams, impaired concentration, confusion, nightmares, paresthesia, and vertigo.

**Respiratory** - asthma, cough, epistaxis, rhinitis, wheezing, bronchitis, dyspnea, pleural effusion, pneumonia, sinusitis.

**Skin** - urticaria, rash, pruritus non-application site, diaphoresis, maculopapular rash, fungal dermatitis, desquamation, dry skin non-application site, hair loss, vesiculobullous rash, sunburn.

**Special Senses** - taste alterations, eye irritation, taste loss, tinnitus.
Urogenital - hematuria, urinary tract infections, metrorrhagia, dysuria, urinary frequency, nocturia, penile infection, proteinuria, vaginal pain.

Laboratory Changes
Significant laboratory changes that have been reported in adult and pediatric patients in clinical trials of cefpodoxime proxetil, without regard to drug relationship, were:

**Hepatic:** Transient increases in AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.

**Hematologic:** Eosinophilia, leukocytosis, lymphocytosis, granulocytosis, basophilia, monocytosis, thrombocytosis, decreased hemoglobin, decreased hematocrit, leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, thrombocythemia, positive Coombs’ test, and prolonged PT, and PTT.

**Serum Chemistry:** Hyperglycemia, hypoglycemia, hypoalbuminemia, hypoproteinemia, hyperkalemia, and hyponatremia.

**Renal:** Increases in BUN and creatinine.

Most of these abnormalities were transient and not clinically significant.

Drug Interactions
**Antacids:** Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H₂ blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., Propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC).

**Probenecid:** As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.

**Nephrotoxic drugs:** Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.

Drug/Laboratory Test Interactions
Cephalosporins, including cefpodoxime proxetil, are known to occasionally induce a positive direct Coombs’ test.

Dosage and Administration
CEFPO Tablet should be administered orally with food to enhance absorption.

The recommended dosages, durations of treatment, and applicable patient population are as described in the following chart:

**Adults and Adolescents (age 12 years and older)**

<table>
<thead>
<tr>
<th>Type of Infection</th>
<th>Total Daily Dose</th>
<th>Dose Frequency</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharyngitis and/or tonsillitis</td>
<td>200 mg</td>
<td>100 mg Q 12 hours</td>
<td>5 to 10 days</td>
</tr>
<tr>
<td>Acute community-acquired pneumonia</td>
<td>400 mg</td>
<td>200 mg Q 12 hours</td>
<td>14 days</td>
</tr>
<tr>
<td>Acute bacterial exacerbations of chronic bronchitis</td>
<td>400 mg</td>
<td>200 mg Q 12 hours</td>
<td>10 days</td>
</tr>
</tbody>
</table>
Uncomplicated gonorrhea (men and women) and rectal gonococcal infections (women)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Dosage</th>
<th>Administration</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and skin structure</td>
<td>800 mg</td>
<td>400 mg Q 12 hours</td>
<td>7 to 14 days</td>
</tr>
<tr>
<td>Acute maxillary sinusitis</td>
<td>400 mg</td>
<td>200 mg Q 12 hours</td>
<td>10 days</td>
</tr>
<tr>
<td>Uncomplicated urinary tract infection</td>
<td>200 mg</td>
<td>100 mg Q 12 hours</td>
<td>7 days</td>
</tr>
</tbody>
</table>

**Patients with Renal Dysfunction**
For patients with severe renal impairment (< 30 mL/min creatinine clearance), the dosing intervals should be increased to Q 24 hours. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.

When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to estimate creatinine clearance (mL/min). For this estimate to be valid, the serum creatinine level should represent a steady state of renal function.

| Males: Weight (kg) x (140 - age) (mL/min) | Females: 0.85 x above value (mL/min) |

**Patients with Cirrhosis**
Cefpodoxime pharmacokinetics in cirrhotic patients (with or without ascites) are similar to those in healthy subjects. Dose adjustment is not necessary in this population.

**Over Dosage**
In acute rodent toxicity studies, a single 5 g/kg oral dose produced no adverse effects.

In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised.

The toxic symptoms following an overdose of beta-lactam antibiotics may include nausea, vomiting, epigastric distress, and diarrhea.

**Presentation**
**Cefpo 100**
Box of 20 tablets

**Cefpo 200**
Box of 20 tablets